329 related articles for article (PubMed ID: 22553244)
1. High-risk human papillomavirus (hrHPV) E6/E7 mRNA testing by PreTect HPV-Proofer for detection of cervical high-grade intraepithelial neoplasia and cancer among hrHPV DNA-positive women with normal cytology.
Rijkaart DC; Heideman DA; Coupe VM; Brink AA; Verheijen RH; Skomedal H; Karlsen F; Morland E; Snijders PJ; Meijer CJ
J Clin Microbiol; 2012 Jul; 50(7):2390-6. PubMed ID: 22553244
[TBL] [Abstract][Full Text] [Related]
2. Comparing triage algorithms using HPV DNA genotyping, HPV E7 mRNA detection and cytology in high-risk HPV DNA-positive women.
Luttmer R; Berkhof J; Dijkstra MG; van Kemenade FJ; Snijders PJ; Heideman DA; Meijer CJ
J Clin Virol; 2015 Jun; 67():59-66. PubMed ID: 25959161
[TBL] [Abstract][Full Text] [Related]
3. Cytology and human papillomavirus testing 6 to 12 months after ASCUS or LSIL cytology in organized screening to predict high-grade cervical neoplasia between screening rounds.
Tropé A; Sjøborg KD; Nygård M; Røysland K; Campbell S; Alfsen GC; Jonassen CM
J Clin Microbiol; 2012 Jun; 50(6):1927-35. PubMed ID: 22518869
[TBL] [Abstract][Full Text] [Related]
4. Sensitivity, specificity, and clinical value of human papillomavirus (HPV) E6/E7 mRNA assay as a triage test for cervical cytology and HPV DNA test.
Benevolo M; Vocaturo A; Caraceni D; French D; Rosini S; Zappacosta R; Terrenato I; Ciccocioppo L; Frega A; Giorgi Rossi P
J Clin Microbiol; 2011 Jul; 49(7):2643-50. PubMed ID: 21525231
[TBL] [Abstract][Full Text] [Related]
5. Performance of human papillomavirus DNA and mRNA testing strategies for women with and without cervical neoplasia.
Tropé A; Sjøborg K; Eskild A; Cuschieri K; Eriksen T; Thoresen S; Steinbakk M; Laurak V; Jonassen CM; Westerhagen U; Jacobsen MB; Lie AK
J Clin Microbiol; 2009 Aug; 47(8):2458-64. PubMed ID: 19535524
[TBL] [Abstract][Full Text] [Related]
6. Comparison of HPV detection technologies: Hybrid capture 2, PreTect HPV-Proofer and analysis of HPV DNA viral load in HPV16, HPV18 and HPV33 E6/E7 mRNA positive specimens.
Keegan H; Mc Inerney J; Pilkington L; Grønn P; Silva I; Karlsen F; Bolger N; Logan C; Furuberg L; O'Leary J; Martin C
J Virol Methods; 2009 Jan; 155(1):61-6. PubMed ID: 18955086
[TBL] [Abstract][Full Text] [Related]
7. Predicting CIN2+ when detecting HPV mRNA and DNA by PreTect HPV-proofer and consensus PCR: A 2-year follow-up of women with ASCUS or LSIL Pap smear.
Molden T; Nygård JF; Kraus I; Karlsen F; Nygård M; Skare GB; Skomedal H; Thoresen SO; Hagmar B
Int J Cancer; 2005 May; 114(6):973-6. PubMed ID: 15645423
[TBL] [Abstract][Full Text] [Related]
8. Diagnostic validity of human papillomavirus E6/E7 mRNA test in cervical cytological samples.
Liu TY; Xie R; Luo L; Reilly KH; He C; Lin YZ; Chen G; Zheng XW; Zhang LL; Wang HB
J Virol Methods; 2014 Feb; 196():120-5. PubMed ID: 24216236
[TBL] [Abstract][Full Text] [Related]
9. HPV E6/E7 mRNA testing is more specific than cytology in post-colposcopy follow-up of women with negative cervical biopsy.
Sørbye SW; Arbyn M; Fismen S; Gutteberg TJ; Mortensen ES
PLoS One; 2011; 6(10):e26022. PubMed ID: 21998748
[TBL] [Abstract][Full Text] [Related]
10. Aptima HPV E6/E7 mRNA test is as sensitive as Hybrid Capture 2 Assay but more specific at detecting cervical precancer and cancer.
Ratnam S; Coutlee F; Fontaine D; Bentley J; Escott N; Ghatage P; Gadag V; Holloway G; Bartellas E; Kum N; Giede C; Lear A
J Clin Microbiol; 2011 Feb; 49(2):557-64. PubMed ID: 21147950
[TBL] [Abstract][Full Text] [Related]
11. p16/ki67 and E6/E7 mRNA Accuracy and Prognostic Value in Triaging HPV DNA-Positive Women.
Giorgi Rossi P; Carozzi F; Ronco G; Allia E; Bisanzi S; Gillio-Tos A; De Marco L; Rizzolo R; Gustinucci D; Del Mistro A; Frayle H; Confortini M; Iossa A; Cesarini E; Bulletti S; Passamonti B; Gori S; Toniolo L; Barca A; Bonvicini L; Mancuso P; Venturelli F; Benevolo M;
J Natl Cancer Inst; 2021 Mar; 113(3):292-300. PubMed ID: 32745170
[TBL] [Abstract][Full Text] [Related]
12. Type-specific human papillomavirus E6/E7 mRNA detection by real-time PCR improves identification of cervical neoplasia.
Andersson E; Kärrberg C; Rådberg T; Blomqvist L; Zetterqvist BM; Ryd W; Lindh M; Horal P
J Clin Microbiol; 2011 Nov; 49(11):3794-9. PubMed ID: 21940473
[TBL] [Abstract][Full Text] [Related]
13. Comparison of human papillomavirus messenger RNA and DNA detection: a cross-sectional study of 4,136 women >30 years of age with a 2-year follow-up of high-grade squamous intraepithelial lesion.
Molden T; Kraus I; Karlsen F; Skomedal H; Nygård JF; Hagmar B
Cancer Epidemiol Biomarkers Prev; 2005 Feb; 14(2):367-72. PubMed ID: 15734959
[TBL] [Abstract][Full Text] [Related]
14. Clinical performance of the PreTect HPV-Proofer E6/E7 mRNA assay in comparison with that of the Hybrid Capture 2 test for identification of women at risk of cervical cancer.
Ratnam S; Coutlee F; Fontaine D; Bentley J; Escott N; Ghatage P; Gadag V; Holloway G; Bartellas E; Kum N; Giede C; Lear A
J Clin Microbiol; 2010 Aug; 48(8):2779-85. PubMed ID: 20573862
[TBL] [Abstract][Full Text] [Related]
15. HPV DNA testing in population-based cervical screening (VUSA-Screen study): results and implications.
Rijkaart DC; Berkhof J; van Kemenade FJ; Coupe VM; Rozendaal L; Heideman DA; Verheijen RH; Bulk S; Verweij W; Snijders PJ; Meijer CJ
Br J Cancer; 2012 Feb; 106(5):975-81. PubMed ID: 22251922
[TBL] [Abstract][Full Text] [Related]
16. Triage of women with minor abnormal cervical cytology: meta-analysis of the accuracy of an assay targeting messenger ribonucleic acid of 5 high-risk human papillomavirus types.
Verdoodt F; Szarewski A; Halfon P; Cuschieri K; Arbyn M
Cancer Cytopathol; 2013 Dec; 121(12):675-87. PubMed ID: 23881840
[TBL] [Abstract][Full Text] [Related]
17. Three-year longitudinal data on the clinical performance of the Abbott RealTime High Risk HPV test in a cervical cancer screening setting.
Poljak M; Oštrbenk A; Seme K; Šterbenc A; Jančar N; Vrtačnik Bokal E
J Clin Virol; 2016 Mar; 76 Suppl 1():S29-S39. PubMed ID: 26643051
[TBL] [Abstract][Full Text] [Related]
18. Risk of high-grade cervical intra-epithelial neoplasia based on cytology and high-risk HPV testing at baseline and at 6-months.
Bulk S; Bulkmans NW; Berkhof J; Rozendaal L; Boeke AJ; Verheijen RH; Snijders PJ; Meijer CJ
Int J Cancer; 2007 Jul; 121(2):361-7. PubMed ID: 17354241
[TBL] [Abstract][Full Text] [Related]
19. Triage of low-grade squamous intraepithelial lesions using human papillomavirus messenger ribonucleic acid tests-A prospective population-based register study.
Reinholdt K; Juul KE; Dehlendorff C; Munk C; Kjaer SK; Thomsen LT
Acta Obstet Gynecol Scand; 2020 Feb; 99(2):204-212. PubMed ID: 31562779
[TBL] [Abstract][Full Text] [Related]
20. Triage of women with minor cervical lesions: data suggesting a "test and treat" approach for HPV E6/E7 mRNA testing.
Sørbye SW; Fismen S; Gutteberg T; Mortensen ES
PLoS One; 2010 Sep; 5(9):e12724. PubMed ID: 20856930
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
